跳至主要内容
临床试验/EUCTR2007-007775-17-DE
EUCTR2007-007775-17-DE进行中(未招募)不适用

A single centre, exploratory, phase II, cross-over, randomised trial, evaluating the effect of spontaneously breathing Helium/Oxygen (65%/35%), to either spontaneously breating Nitrogen/Oxygen (65%/35%) on the Six-Minute Walking Distance in severe COPD patients - Lung Function Exercising

Air Liquide0 个研究点目标入组 24 人开始时间: 2009年7月3日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Air Liquide
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Male or female aged 45 and 80 years old,
  • - Patient with documented clinical diagnosis of hypercapnia and stage III or IV COPD (according to GOLD 2008 guidelines)
  • - Patient with stable COPD in the four weeks prior to selection as evidenced by no i.v. COPD medication, no treatment for COPD in an emergency, no acute intensive care setting, no intake of antibiotics and stables ph,
  • - Current or ex-smoker with a smoking history of 10 pack-years or more
  • - Patient used to supported Non-Invasive Ventilation (NIV),
  • - Patient willing an able to complete the requierments of the study in one month or less, including repeated pulmonary function tests and Six-Minute Walk Tests,
  • - Patient having dated and signed his/her written informed consent after full explanation of the study by the investigator, prior to study participation
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Inability or contra-indication to perform pulmonary function tests,
  • - Inability or contra-indication to perform the Six-Minute Walk Test with a trolley,
  • - Any contra-indication to receive Non-Invasive Ventilation (NIV),
  • - Obese patient having a Body Mass Index (BMI) < 35,
  • - Pregnant or lactating woman,
  • - Female patient of child-bearing potential with lack of efficient contraception (as defined in CPMP/ICH/286/95 guideline (note 3)),
  • - Unstable COPD or any other past or present significant respiratory disease,
  • - Clinically significant or uncontrolled pathologie conditions which may interfere with the study procedures or endager the patient,
  • - Drug abuse or psychic disorders resulting in the inability to fully understand the requirements of the study,
  • - Legal status which prohibitis informed consent,
  • - Participation in any interventional clinical trial within 30 days prior to selection or current participation in another investigational product trial

研究者

发起方
Air Liquide

相似试验

进行中(未招募)
1 期
Establishing a dose of hormone supplementation in trauma patients that will increase hormone levels in the bodyDHEA depletion in trauma and hip fracture patients.MedDRA version: 20.0 Level: PT Classification code 10056629 Term: Dehydroepiandrosterone decreased System Organ Class: 10022891 - Investigations
EUCTR2016-004250-15-GBniversity Hospitals Birmingham270
进行中(未招募)
1 期
A PHASE II, SINGLE-CENTRE, PROSPECTIVE EXPLORATORY TRIAL TO ASSESS THE EFFICACY OF LANREOTIDE AUTOGEL 120 MG IN THE SYMPTOMATIC TREATMENT OF ACUTE RADIATION INDUCED DIARRHEA
EUCTR2016-001790-33-BEniversity Hospital Ghent40
进行中(未招募)
不适用
A phase II, open, single centre, exploratory study to evaluate the safety and immunogenicity of one booster dose of a GSK Biologicals’ Hepatitis B vaccine Engerix™-B or a of GSK Biologicals’ HIV candidate vaccine (732461), administered intramuscularly, in conjunction with the administration of a single oral dose of chloroquine in healthy adults. - EARLY-CLINRES-004Immunisation against Hepatitis B and HIV in healthy adults aged between 18-52 years old, inclusive.
EUCTR2009-012223-29-BEGlaxoSmithKline Biologicals
已完成
2 期
The Hunter Humira and Endothelial Function in Early Rheumatoid Arthritis TrialMusculoskeletal - Other muscular and skeletal disordersCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemInflammatory and Immune System - Rheumatoid arthritisCardiovascular DiseaseRheumatoid Arthritis
ACTRN12611000972921A/Prof Stephen Oakley60
进行中(未招募)
1 期
An exploratory phase II, single arm, multicenter study to evaluate the efficacy and safety of the combination of pertuzumab and Herceptin® (trastuzumab) in patients with HER2-positive metastatic breast cancer.MedDRA version: 9.1 Level: LLT Classification code 10027475 Term: Metastatic breast cancerMetastatic breast cancer
EUCTR2005-003493-19-GBF. Hoffmann-La Roche Ltd95